BioAge Labs, Inc. (BIOA)
BIOA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that BioAge Labs, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / January 8, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against BioAge Labs, Inc. ("BioAge" or "the Company") (NASDAQ:BIOA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired BioAge securities pursuant to the registration statement and prospectus issued in connection with the Company's September 26, 2024 initial public offering ("IPO").
March 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - BIOA
NEW YORK, NY / ACCESSWIRE / January 8, 2025 / If you suffered a loss on your BioAge Labs, Inc. (NASDAQ:BIOA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Levi & Korsinsky Reminds BioAge Labs, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - BIOA
NEW YORK, NY / ACCESSWIRE / January 7, 2025 / If you suffered a loss on your BioAge Labs, Inc. (NASDAQ:BIOA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
BioAge Labs, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA
NEW YORK, NY / ACCESSWIRE / January 7, 2025 / If you suffered a loss on your BioAge Labs, Inc. (NASDAQ:BIOA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
BioAge Labs, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights – BIOA
NEW YORK, NY / ACCESSWIRE / January 7, 2025 / If you suffered a loss on your BioAge Labs, Inc. (NASDAQ:BIOA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Investors in BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA
NEW YORK, NY / ACCESSWIRE / January 7, 2025 / If you suffered a loss on your BioAge Labs, Inc. (NASDAQ:BIOA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
BIOA BREAKING NEWS: A Class Action Lawsuit has been filed against BioAge Labs, Inc. in Connection with 76% Stock Drop - Investors with Losses are Urged to Contact BFA Law
NEW YORK, NY / ACCESSWIRE / January 7, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ:BIOA) and certain of its senior executives for potential violations of the federal securities laws. If you invested in BioAge, you are encouraged to obtain additional information by visiting Click Here
BIOA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that BioAge Labs, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / January 7, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against BioAge Labs, Inc. ("BioAge" or "the Company") (NASDAQ:BIOA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired BioAge securities pursuant to the registration statement and prospectus issued in connection with the Company's September 26, 2024 initial public offering ("IPO").
Shareholders of BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA
NEW YORK, NY / ACCESSWIRE / January 7, 2025 / If you suffered a loss on your BioAge Labs, Inc. (NASDAQ:BIOA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Investors With Losses Are Invited To Join The Schall Law Firm In An Inquiry Into BioAge Labs, Inc. For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / January 7, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BioAge Labs, Inc. ("BioAge" or "the Company") (NASDAQ:BIOA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Levi & Korsinsky Investigates Possible Securities Fraud Violations by BioAge Labs, Inc. (BIOA)
NEW YORK, NY / ACCESSWIRE / January 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of BioAge Labs, Inc. ("BioAge Labs, Inc.") (NASDAQ:BIOA) concerning possible violations of federal securities laws. After the company discontinued its STRIDES Phase 2 trial for azelaprag, citing safety concerns over elevated liver transaminase levels in participants.
An Investigation Has Commenced on Behalf of BioAge Labs, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your BIOA Losses.
NEW YORK, NY / ACCESSWIRE / January 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of BioAge Labs, Inc. ("BioAge Labs, Inc.") (NASDAQ:BIOA) concerning possible violations of federal securities laws. After the company discontinued its STRIDES Phase 2 trial for azelaprag, citing safety concerns over elevated liver transaminase levels in participants.
